Illumina announced a $7.1 billion acquisition of Grail in 2020, but the European Commission, the EU’s executive arm, said the company broke the bloc’s merger rules by completing the deal without its consent. The EU had announced last year that it was blocking the merger, saying it would hurt competitors.
San Diego-based Illumina is a major supplier of next-generation sequencing systems for genetic and genomic analysis, while Grail is a health company developing blood tests to try to catch cancer early. The commission says companies almost invariably play by the rules and wait to complete an acquisition or merger until antitrust authorities have cleared it.
대한민국 최근 뉴스, 대한민국 헤드 라인
Similar News:다른 뉴스 소스에서 수집한 이와 유사한 뉴스 기사를 읽을 수도 있습니다.
출처: AP - 🏆 728. / 51 더 많은 것을 읽으십시오 »